AUAUniversity

Comorbid Conditions in the Patient with Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/37727

LEARNING OBJECTIVES:

At the conclusion of these activities, participants will be able to:

1. Oversee comorbidities and describe their management in the context of advanced prostate cancer treatment.

2. Assess the potential cardiovascular risk associated with ADT.

3. Differentiate the roles of the urologist, other specialists and advanced practice providers and identify opportunities for shared care and team-based approaches of patients with prostate cancer.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Myovant Sciences LTD

Pfizer, Inc.

Advances in ADT: A Guide for Urologists and APPs

CME Available: https://auau.auanet.org/node/37866

At the conclusion of this activity, participants will be able to:

1. Identify and treat a patient with new diagnosed M1 prostate cancer with ADT plus be able to offer additional therapies that extend survival.

2. Analyze the risks and benefits of treatment for M1 HSPC, MO CRPC, and M1 CRPC.

3. Differentiate the clinical significance of GnRH agonists vs. GnRH antagonists and newer treatments that complement these options.

4. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.

5. Facilitate discussions with patients and caregivers regarding ADT and advanced prostate cancer treatment.

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Myovant Sciences LTD

Pfizer Inc.

AUA2022 JU Lecture: Engaging Patients: A Challenge to our Care Delivery and Research Priorities

Speaker: Angela Smith, MD, MS

University of North Carolina at Chapel Hill

AUA2022 Ramon Guiteras Lecture: How to Reach Excellence in Urology: Challenges and Opportunities

Speaker: Francesco Montorsi, MD

AUA2022 John Duckett Memorial Lecture: Lifelong Learning, What’s in it for me?

Speaker: David Joseph, MD

Professor of Urology / Vice Chair Academic Affairs / Beverly P. Head Chair in Pediatric Urology at Children's of Alabama

Children's of Alabama

AUA2022 John K. Lattimer Lecture: Testosterone, Science and Human Dignity

Speaker: Abraham Morgentaler, MD, FACS

AUA2022 Presidential Address

Speaker: Raju Thomas, MD, FACS, FRCS, MHA

Urology Chair, Tulane University Medical Center and AUA President

Tulane University

PARP Inhibitors in Advanced Prostate Cancer Care Podcast

CME Available: https://auau.auanet.org/node/37321

Host: Jay D. Raman, MD, FACS

Guests: Maha Hussain, MD and Ganesh Raj, MD, PhD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.

2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.

3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.

4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Advancing Women in Urology: Sponsorship and It’s Role in Career Advancement in Medicine

Host: Jay D. Raman, MD, FACS

Guest: Peggy Pearle, MD and Simone Thavaseelan, MD

Outline:

Segment #1 Defining Sponsorship

Segment #2 Role in Career Advancement/Importance

Segment #3 Identifying the Issue

Segment #4 Key Characteristics of healthy/effective Sponsorship

Segment #5 Opportunities for Action

ACKNOWLEDGEMENT

This educational series was made possible by support from Urovant

Resources:

Jain, S. Why Sponsorship in Medicine Matters. Wolters Kluwer Health, https://www.wolterskluwer.com/en/expert-insights/why-sponsorship-in-medicine-matters (2020).

Ayyala, M.S., et al. Mentorship Is Not Enough: Exploring Sponsorship and Its Role in Career Advancement in Academic Medicine. Acad Med. 94, 94-100 (2019).

Lewiss R.E., et al. Is Academic Medicine Making Mid-Career Women Physicians Invisible? J Womens Health (Larchmt). 29,187-192 (2020).

Tesch, B.J., Wood, H.M., Helwig, A.L., Nattinger, A.B. Promotion of women physicians in academic medicine. Glass ceiling or sticky floor? JAMA. 273,1022-5 (1995).

Silva, C. Study: Women Get Fewer Game Changing Leadership Roles. Harvard Business Review, https://hbr.org/2012/11/study-women-get-fewer-game-changing

Hewlett, S.A., Peraino, K., Sherbin, L., Sumberg, K. The Sponsor Effect: Breaking Through the Last Glass Ceiling. Boston, Mass Harvard Business Review (2011).

Richter, K.P., et al. Women Physicians and Promotion in Academic Medicine. N Engl J Med. 383, 2148-2157 (2020).

Foust-Cummings H. Sponsoring Women to Success. Catalyst, http://www.catalyst.org/system/files/sponsoring_women_to_success.pdf. (2011)

Velez, D., et al. Rising Tides: Challenges and Opportunities for Women in the Urologic Workforce. Urology. 150, 47-53 (2021).

Harris, C. How to find the person who can help you get ahead at work. TEDWomen, https://www.youtube.com/watch?v=gpE_W50OTUc.(2018).

Penaloza NG,, et al. Someone Like Me: An Examination of the Importance of Race-Concordant Mentorship in Urology. Urology. 22. (2022)

Butler, P.D. When excellence is still not enough. Am J Surg. 220, 543-544 (2020)

Addressing Disparities and Variations in Care in GU Oncology

CME Available: auau.auanet.org/node/37337

Host: Jay D. Raman, MD, FACS

Guests: Kelvin Moses, MD, PhD and Svetlana Avulova, MD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Discuss the impact of race and cultural barriers on optimal GU cancer care.

2. Evaluate financial toxicity as a barrier to optimal patient care in urologic cancer.

3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme